2025년 10월 신약개발관련 주요 Deal ◈본문 주요 라이센싱 및 파트너십 No Date Investors/ Licensee Service Provider/ Licensor Assets MoA Indication Stage Value (USD Mn) 1 10/6 Chiesi group Arbor Biotechnologies ABO-101 GOX inhibitors Metabolic disorder Primary hyperoxaluria type 1 Phase 1/2 2,115 2 10/6 AstraZeneca Algen Biotechnologies AlgenBrain™ AI-drivenfunctional genomicsplatform Immunology - - 555 3 10/8 Zenas BioPharma InnoCare Pharma OrelabrutinibObexelimab BTK inhibitor CD19 xFcγRIIbBsAbs Immunology Immunology Multiple sclerosis IgG4-RD Phase 3 Phase 3 2,000 4 10/10 Chugai Pharmaceutical Roche CT-388 GLP-1R x GIPR dual modulator Metabolic disorder Obesity, T2D Phase 2 n/d 5 10/14 Takeda Nabla Bio JAM(Joint AtomicModel) AI protein design platform - - - 1,000 6 10/15 Boehringer Ingelheim Aimed Bio n/d ADC Oncology n/d n/d 991 7 10/15 Novo nordisk Omeros Zaltenibart(OMS906) MASP-3 inhibitor Hematology paroxysmal nocturnal hemoglobinuria(PNH) Phase 2 2,100 8 10/16 Dianthus Therapeutics Nanjing LeadsBiolabs DNTH212(LBL-047) Bifunctional BDCA2 and BAFF/APRIL inhibitor Immunology Autoimmune disease; Sjögren`ssyndrome, SLE, Dermatomyositis, Hidradenitissuppurativa, Scleroderma, Pemphigusvulgaris Phase 1 1,000 9 10/17 Roche Hansoh Pharma HS-20110 CDH17 ADC Oncology Colorectal cancer Phase 1 1,450 10 10/20 Lundbeck Contera Pharma AttackPoint Discovery®, OligoDisc®, SpliceMatrix® RNA discovery platforms Neurology Brain diseases n/d n/d 11 10/21 Samsung Bioepis Phrontline Biopharma TJ108 EGFR x HER3 Bispecific, dual-payloadADC Oncology Solid tumors; NSCLC Preclinical n/d 12 10/21 Takeda Innovent Biologics IBI363 IBI343 IBI3001 PD-1 xIL-2RαBsAbs CLDN18.2 ADC EGFR x B7-H3 Bispecific ADC Oncology Oncology Oncology sqNSCLC; MSS CRC Gastric cancer, Pancreatic cancer Advanced or metastatic solid tumor Phase 2 Phase 3 Phase 1 11,400 13 10/24 Biogen Vanqua Bio n/d C5aR1 antagonist Immunology Neutrophil-mediated inflammation Preclinical 1,060 14 10/27 GSK Syndivia n/d ADC Oncology mCPRC Preclinical 357 15 10/28 GSK Empirico EMP-012 GaINAc-conjugated siRNA Immunology COPD Phase 1 745 16 10/29 Regeneron Pharmaceuticals ModeX Therapeutics MSTAR Platform Generatingmultispecific antibodiesplatform Immunology, Oncology, Metabolicdisorder n/d - 1,007 17 10/29 Everest Medicines Visera(NovaBridge) VIS-101 VEGF-A x ANG2 BsAbs Ophthalmology wAMD, DME, RVO Phase 2 96 (n/d=non-disclosure) 주요 M&A No Date Acquires Issuer Assets MoA Indications Status Value (USD Mn) 1 10/9 Novo Nordisk Akero Therapeutics Efruxifermin FGF21 agonist Metabolic disorder MASH Phase 3 5,200 2 10/10 BMS Orbital Therapeutics OTX-201 CD19 CAR-T Immunology Autoimmune disease Preclinical 1,500 3 10/14 BioCryst Pharmaceuticals Asteria Therapeutics Takhzyro αKLKB1 mAb Immunology Hereditary angioedema (HAE) Marketed 700 4 10/22 Ipsen ImCheck Therapeutics ICT01 αBTN3AmAb Oncology AML Phase 1/2 1,160 5 10/22 Alkermes Avadel Pharmaceuticals Lumryz GABA B receptor agonist Neurology Excessive sleepiness Marketed 2,100 6 10/24 Eli Lilly Adverum Biotechnologies Ixo-vec Gene therapy Ophthalmology wAMD Phase 3 262 7 10/26 Novartis Avidity Biosciences - AOC Platform Neurology DM1; FSHD; DMD Phase 3 12,000 Reference 각 사 홈페이지/ BioCentury / Globaldata / Cortellis / Fierce Biotech ...................(계속) ☞ 자세한 내용은내용바로가기또는첨부파일을 이용하시기 바랍니다.